Blog

Did you foresee this £12M cost increase coming?

October sees World Mental Health Day marked and recognised across the globe. The overall objective of the day is to raise awareness of mental health issues and mobilise efforts in support of better mental health. This year’s focus? Mental health in the workplace.

Globally, the WHO reports, “more than 300 million people suffer from depression, the leading cause of disability. More than 260 million are living with anxiety disorders. Many of these people live with both.

The rising costs of mental health disorders

A recent WHO-led study estimates that depression and anxiety disorders cost the global economy US$ 1 trillion each year in lost productivity.” That’s no small sum.

The Guardian reports that 2016 saw the NHS prescribing “a record number of antidepressants, fuelling an upward trend that has seen the number of pills given to patients more than double over the last decade.” (The Guardian)

To demonstrate this, our analysis of the current tariff increase – due to temporary supply issues – of the generic antipsychotic drug Quetiapine (IR) in the UK, shows just how volatile the NHS’s bill for mental health can be.

Quetiapine (IR) in the UK

At-a-glance MarketView analytics

Our interrogative analytics of NHS GP Prescribing Data reveals that the monthly cost to the NHS of Quetiapine (IR)s has risen by over £12M per month in June and July. This ‘temporary’ price concession is still in place now, so the 5 months to October will result in a £50M+ extraordinary cost to the NHS, from just one drug. To put this in context the cost of protecting the whole country from flu with the ‘flu jab’ – costs the NHS around £100M per year.

Inspiremed’s rapid-fire analysis provides valuable insights from NHS and IMS prescription data at the touch of a button. And presents findings in clear easy-to-analyse visualisation dashboards like the one we picture here.

Drill down to key data sets, remove the complexities of data analysis and drive effective sales and marketing activities with real time data.

Book my demonstration

“Comprehensive, flexible, efficient and professional. A recent training program for our sales team was both well delivered and received. Any bespoke amends to the tool are quickly implemented in line with our requirements.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“The budget impact models are a real benefit.”

National Sales Manager, UK Pharmaceutical Company

“Obviously I wouldn’t recommend Rx Analyser to our direct competitors as I believe the level of insight provided really gives us an edge.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“Rx Analyser is already having a significant impact on our business, allowing our Territory Managers to focus on established CCG accounts and identify practice level successes and others for further development.”

Managing Director, UK Diabetes Healthcare Company

“I use the data from RXA Budget Impact Model daily. It is the core of everything we do! I cannot recommend the model more. It has had a substantial impact on our business across the board and I would not be without it.”

Country Manager UK, Leading Diagnostics Company

“Working with Inspiremed is a great partnership experience and they make sure they understand your business, the industry that you are in and what you want to achieve in the use of the product.”

National Sales Manager, UK Pharmaceutical Company

Sign up for added insights